Etigilimab (MPH313)
For patients with advanced or metastatic solid tumors
Our pipeline currently consists of six clinical-stage product candidates.
We have already delivered three successful Phase 2 studies with a Phase 2 and Phase 1b/2 ongoing.
Lead indication: The treatment of severe Alpha-1 Antitrypsin Deficiency (“AATD”). Investigator led studies into additional indications ongoing.
We have two additional programs with current partnering opportunities. Navicixizumab has been licensed out to OncXerna.
For the treatment of platinum-resistant ovarian cancer. Navicixizumab has been partnered with OncXerna Therapeutics Inc. for further development.
For the treatment of acute exacerbations of chronic obstructive pulmonary disease (“AECOPD”).
For the treatment of male infertility associated with hypogonadotropic hypogonadism (“HH”).
Mereo BioPharma announces positive topline results from ASTRAEUS a Phase 2 trial of alvelestat in Alpha-1 Antitrypsin Deficiency- associated Emphysema.
Mereo BioPharma Group plc today announced it will host a conference call on Monday, May 9, 2022 at 10:30 a.m. ET to review top-line clinical data from its “ASTRAEUS” Phase 2 Study of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema.
Mereo BioPharma's partner for the development of Navicixizumab, OncXerna Therapeutics Inc. announced that Navicixizumab Phase 1b data has been published in the Journal of Clinical Oncology.
Mereo BioPharma's partner for the development of setrusumab, Ultragenyx Pharmaceutical Inc. today announced the first patient has been dosed in a clinical study for the treatment of Osteogenesis Imperfecta (OI) in patients ages 5 to <26 years of age